618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster II

Targeting CCL3 mono like LSC overcomes chemotherapy resistance in NPM1 mutant AML

Morphologic leukemia free state MLFS is associated with inferior outcomes in patients with Acute Myeloid Leukemia AML treated with front line azacitidine plus venetoclax

17p cytogenetic changes in TP53 mutated AML

Cholesterol biosynthesis related genes reveal new opportunities for risk stratification and treatment in Acute Myeloid Leukemia

A blood based protein signature adds to genomic prognostication of survival in TP53 mutated Acute Myeloid Leukemia

Functional plasma cell signatures mark AML chemotherapy responders Evidence from immune niche profiling

Chromosome genomic array testing CGAT improves diagnostic yield in patients with AML and MDS and has the potential for better risk stratefication an NCI myelomatch and SWOG report

Dogs with acute leukemia have shared and unique genetic mutations compared to human acute leukemia

1 200 U2AF1 mutations reveal distinct clinicobiological features of the S34 Q157 co mutation subgroup

Low protein expression of Janus kinase 2 JAK2 is prognostically adverse and independent of mutation status in acute myelogenous leukemia

Changing dogma regarding mutation primacy in acute myelogenous leukemia Protein expression supersedes mutation status

The laminin receptor integrin a7ß1 marks a highly migratory cell population and correlates with poor prognosis in Acute Myeloid Leukemia

Dynamics of leukemic blast and immune cell populations in Acute Myeloid Leukemia

Eccdna encoded LIPIN1 drives DGAT1 dependent lipid droplet biogenesis to promote Acute Myeloid Leukemia progression and chemoresistance

Identifying treatment response in AML through a multi omics classifier of malignant cell states

Integrative analysis of the interplay between peripheral immune landscape and leukemic blast adaptation in Acute Myeloid Leukemia

Which molecular patterns of high risk myeloid malignancies are concordantly identified using two machine learning algorithms

EV mirnas predict outcomes in pediatric AML A pilot study

A baseline transcriptomic signature predictive of clinical response to menin inhibitors in AML The PRE men retrosprospective Study

CD132 expression promotes AML aggressiveness via the JAK STAT signaling pathway

Computational profiling of predicted neoantigen landscape reveals differential immunogenicity at AML diagnosis and relapse

Integrating EVI1 expression into prognostic models for MDS Insights from IPSS R and IPSS m subgroup analyses

The impact of monocytic phenotype and NPM1 mutation status in Acute Myeloid Leukemia when treated with traditional induction chemotherapy compared to azacitidine and venetoclax

SNAI2 orchestrates a hypo oxidative mitochondrial phenotype with elevated FAO dependence in acute myeloid leukemia

ESAM is functionally involved in the activity of cancer stem like cells in human acute myeloid leukemia

Transcriptomic subclasses of KMT2A and NUP98 gene fusions in adolescent and adult Acute Myeloid Leukemia

DNA methylation profiling identifies two epigenetic subgroups with prognostic implications in pediatric acute promyelocytic leukemia The JCCG study JPLSG AML P05

Improving karyotype success for myelomatch Evidence based culturing optimization for rapid AML screening an NCI myelomatch and SWOG report

NRAS mutation drives excessive netosis and differentiation syndrome in acute promyelocytic leukemia

Developing artificial intelligence based transcriptomic signature for selecting patients with HOXA MEIS1 pathway abnormalities for the treatment with menin inhibitors

Abnormal metabolic activation of CD8 t cells correlates with poor prognosis in acute myeloid leukemia

AML maturation stages associate with disease permissive and immunosuppressive effects in newly diagnosed AML patients An analysis at the single cell level